S H E A R M A N & S T E R L I N G L L P | 8 5
COMPLIANCE
For nearly two decades, reverse payments
have been the perennial focus in the
pharmaceutical industry and among antitrust
professionals. But while courts continue to
grapple with the implications of the Supreme
Court's decision in FTC v. Actavis, Inc.,
570 U.S. 136 (2013), more attention is being
brought to pharmaceutical companies'
lifecycle management strategies.
Continued overleaf
MOVING PAST
ACTAVIS WITH
EVOLVING
LIFECYCLE
MANAGEMENT
STRATEGIES
BY JESSICA DELBAUM AND TIMOTHY SLATTERY
